Document is current
Any future updates will be listed below
-
Authors
,
Poletti, V.
Vancheri, C.
Albera, C.
Harari, S.
Pesci, A.
Metella, R. R.
Campolo, B.
Crespi, G.
Rizzoli, S.
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 26 June 2020
Accepted: 29 January 2021
First Online: 24 February 2021
Ethics approval and consent to participate
: The study protocol was approved in July 2015 by an institutional review board/ethics committee (107/2015/PO del registry EC), and written informed consent was obtained for all patients.
: Not applicable.
: BC was an employee of Boehringer Ingelheim (Italy) at the time of this study. GC is an employee of Boehringer Ingelheim. SR is an employee of MediNeos Observational Research (Modena, Italy). AP has received personal (speaker/advisory board) fees from Boehringer Ingelheim and Roche, and his research activity is partially supported by project Premia. SH has acted as a clinical trial investigator, participated in scientific advisory boards, and delivered lectures for Boehringer Ingelheim, Roche and Actelion. He has also received research grants from Boehringer Ingelheim. CA has acted as a clinical trial investigator for Boehringer Ingelheim and Roche, participated in scientific advisory boards for Boehringer Ingelheim, Roche, MSD, Fibrogen and GSK, and received research grants from Boehringer Ingelheim and Roche. CV has received research grants and personal fees from Boehringer Ingelheim and Roche. VP has received personal fees from Boehringer Ingelheim. RRM has nothing to disclose.
